臭氧和普卡因增加了富血小板血中血小板衍生因子的分泌
Chiara Rita Inguscio1, Barbara Cisterna2, Maria Assunta Lacavalla3
1Department of Neurosciences, Biomedicine and Movement Sciences, Anatomy and Histology Section, University of Verona. chiararita.inguscio@univr.it.
European journal of histochemistry : EJH
|October 11, 2023
概括
富于血小板的血 (PRP) 与臭氧或普卡因相结合,可增强血小板因子的释放. 这些药物通过不同的途径刺激血小板,而不会造成损伤,从而提高治疗潜力.
科学领域:
- 再生医学是一种再生医学.
- 血小板生物学 血小板生物学
- 生物材料科学 生物材料科学
背景情况:
- 富血小板血 (PRP) 是再生医学中的一个关键疗法,利用来自血小板的生物活性分子.
- 在PRP中的生长因子和细胞因子驱动组织修复,细胞增殖和免疫调节.
- 通过组合疗法提高PRP的治疗疗效是研究的一个活跃领域.
研究的目的:
- 研究臭氧和普罗卡因对PRP中的血小板功能和因子释放的体外影响.
- 评估臭氧和普卡因对血小板形态功能修饰和分泌因子的联合影响.
- 评估作为PRP辅助剂的臭氧和普罗卡因的安全性和再生潜力.
主要方法:
- 在试验室中用臭氧,普罗卡因或两者一起对PRP进行处理.
- 传输电子显微镜用于详细的血小板超结构分析.
- 生物分析试验量化释放的血小板衍生因子的度.
主要成果:
- 臭氧处理增加了血小板表面突起和开放式管系统扩张,表明α-颗粒的释放.
- 普罗卡因治疗减少了表面突起,但显著增加了微囊的释放,表明高分泌活性.
- 在13个分析的血小板衍生因子中,有9个因子在臭氧和/或普卡因治疗后显著增加了血清PRP.
- 臭氧和普罗卡因通过不同的生理途径刺激血小板,而不会引起细胞损伤.
结论:
- 臭氧和普罗卡因作为PRP的强有力的兴奋剂,增强关键再生因素的释放.
- 由臭氧和普罗卡因激活的独特分泌途径提供了一种多功能方法来调节PRP的治疗特性.
- 将PRP与臭氧或普洛卡因结合在一起,是扩大临床应用中的再生潜力的有希望的策略.
相关概念视频
01:22Formation of the Platelet Plug
6.5K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.5K
01:18Structure and Function of Platelets
1.2K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
1.2K
01:16Clot Retraction and Fibrinolysis
6.3K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.3K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
538
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
538
01:05Introduction to Hemostasis
8.1K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
8.1K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
8.1K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
8.1K